ArriVent BioPharma, Inc. Common Stock (AVBP) is a publicly traded Healthcare sector company. As of May 20, 2026, AVBP trades at $27.24 with a market cap of $1.26B and a P/E ratio of -6.20. AVBP moved +4.09% today. Year to date, AVBP is +39.38%; over the trailing twelve months it is +30.49%. Its 52-week range spans $15.47 to $36.37. Analyst consensus is strong buy with an average price target of $44.33. Rallies surfaces AVBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ArriVent Banks $326.4M Cash, ARR-002 IND Cleared, Firmonertinib Data Due Mid-2026: ArriVent reported $326.4 million in cash and investments as of March 31, 2026, funding operations into Q4 2027 with Q1 net cash usage of $41.9 million. The company secured FDA IND clearance for dual-target ADC ARR-002 and expects pivotal firmonertinib EGFR exon 20 data mid-2026.
| Metric | Value |
|---|---|
| Price | $27.24 |
| Market Cap | $1.26B |
| P/E Ratio | -6.20 |
| EPS | $-4.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $36.37 |
| 52-Week Low | $15.47 |
| Volume | 400.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-166.31M |
| Gross Margin | 0.00% |
9 analysts cover AVBP: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.33.